KL-A167 Injection

DRUG2 trials

Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Conditions

Nasopharyngeal CarcinomaRecurrent or MetastaticSmall Cell Lung Cancer

Phase 2

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

CompletedNCT03848286

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Nasopharyngeal Carcinoma, Recurrent or Metastatic

Start: 2019-03-06End: 2022-01-13Updated: 2023-10-23

SKB500 Combinations in Patients With Small Cell Lung Cancer

RecruitingNCT07296809

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Small Cell Lung Cancer

Start: 2026-01-30End: 2029-12-31Target: 80Updated: 2026-04-02

Related Papers

Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.

2024-09-183 citations

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.

2022-10-1021 citations